Pharmaceuticals company Bajaj Healthcare announced Q1FY26 results Revenue from operations stood at Rs 1,488.4 million, up 12.5% year-on-year EBITDA was Rs 253.9 million, largely flat with a 0.1% YoY increase EBITDA margin stood at 17.0%, compared to 19.1% in Q1FY25 PAT from continuing operations came in at Rs 121.7 million, rising 51.7% YoY PAT margin from continuing operations improved to 8.1% from 6.0% Loss from discontinued operations narrowed to Rs 3.4 million from Rs 8.9 million Total profit for the period stood at Rs 118.3 million, up 65.9% YoY Overall profit margin rose to 7.9% from 5.4% in Q1FY25 Commenting on the Results, Anil Jain – Managing Director said, “Q1 FY26 marks a strong and promising start to the new fiscal year for Bajaj Healthcare, despite a challenging pricing environment in certain segments. Revenue from operations rose 12.5% year-onyear to Rs 1,488.4 million, while PAT grew by 66% to Rs 118.3 million, reflecting improved profitability and sharper execution across business segments. EBITDA remained steady at Rs 253.9 million, with margins improving sequentially to 17.0% from 15.1%, reflecting better product mix and improved operating leverage, even amidst input cost pressures. Segment-wise, our API export business delivered standout growth of 68.4% YoY, supported by growing demand in regulated markets and the ramp-up of commercial CDMO supplies. Formulations saw 41.1% year-on-year growth, led by deeper market penetration and new strategic partnerships. Due to pricing headwinds in the domestic API segment, the company has strategically realigned its portfolio towards value-added exports and differentiated molecules to reinforce growth and profitability. ….We are pleased to report that during the quarter, we received three new CEP approvals and one ASMF approval from European regulatory authority, further strengthening our position in regulated EU/UK markets. Following product approvals, validation batch supplies have commenced for a few molecules under CDMO agreements. In parallel, five DMFs were filed with the UK MHRA to enable future commercial supply and regulatory compliance. To date, we have filed a total of nine CEPs, out of which seven have been approved. Furthermore, four additional CEP filings are in process. Our CNS portfolio continues to evolve with notable regulatory developments. Cenobamate has received a positive recommendation from the Subject Expert Committee (SEC) and is currently awaiting final DCGI approval to initiate Phase III trials. For Magtein®, validation batches are underway, with commercial launch targeted in Q3. These developments mark important steps toward expanding our product pipeline. Backward integration continues to be a cornerstone of our strategy, especially in supporting scale-up across CDMO and formulation segment. Export contribution rose to 35% of total revenue, up from 23% last year, reflecting stronger API demand and deeper access to global markets. We remain firmly on course to build a value-driven, innovation-led growth engine across APIs, formulations, and CDMO.” Result PDF